Concentration‐QTc analysis of soticlestat in healthy adults: An alternative to a thorough QT study
British Journal of Clinical Pharmacology · 2025
DOI: 10.1111/bcp.16255 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Wei Yin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Takeda Pharmaceutical Company Ltd, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Long QT Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Takeda Pharmaceutical Company Ltd, Takeda Canada.
Abstract (Originalsprache)
Aim
This study aimed to examine the cardiac and overall safety and pharmacokinetic (PK) profiles of soticlestat (TAK‐935), an oral, first‐in‐class selective cholesterol 24‐hydroxylase inhibitor.
Methods
Data came from a randomised, phase 1 study of soticlestat in 33 healthy Japanese adults (NCT04461483); 24 adults in Part 1 (single‐dose soticlestat 200‐1200 mg or placebo) and 9 in Part 2 (soticlestat 100‐300 mg twice daily or placebo for 21 days). PK sample collection was paired with 12‐lead electrocardiogram data from continuous Holter recordings. The concentration‐QTc relationship was analysed using a linear mixed‐effects model. QTc prolongation safety margins were determined for two scenarios of calculated high clinical exposures: scenario 1 (NCT05064449) involved coadministration of single‐dose soticlestat 300 mg with itraconazole or mefenamic acid and scenario 2 (NCT05098054) involved single‐dose soticlestat 300 mg administration in participants with mild/moderate hepatic impairment (implementing a 3‐fold dose reduction for moderate severity).
Results
Based on concentration‐QTc analysis, placebo‐corrected change‐from‐baseline QT values (90% confidence intervals), corrected for heart rate (Fridericia's method), were 0.94 ms (−2.35, 4.23) for soticlestat and 0.63 ms (−3.15, 4.41) for its N‐oxide metabolite plasma concentrations at therapeutic doses (soticlestat 300 mg twice daily); safety margins were >2‐fold for scenarios of calculated high clinical exposures. No (Part 1) and five (83.3%; Part 2) participants experienced treatment‐emergent adverse events (all mild).
Conclusion
There was no evidence for QT prolongation with soticlestat at therapeutic doses or in two scenarios of high clinical exposures, which resulted in regulatory agencies waiving requirements of a thorough QT study. Safety/PK findings aligned with previous soticlestat clinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Takeda Pharmaceutical Company Ltd, Cambridge, Massachusetts, USA.
- PRA Development Center K.K., Osaka, Japan.
- Clinical Research Hospital Tokyo, Tokyo, Japan.
- Takeda Development Center Japan, Takeda Pharmaceutical Company Ltd, Osaka, Japan.
- Clario, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Wei Yin
Förderung
- Takeda Pharmaceutical Company Ltd
- Takeda Canada
Zitieren
APA
Yin, W., Dote, N., Fukase, H., Imazaki, M., Shimizu, K., Takeda, S., Darpo, B., Xue, H., & Asgharnejad, M. (2025). Concentration‐QTc analysis of soticlestat in healthy adults: An alternative to a thorough QT study. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16255
Vancouver
Yin W, Dote N, Fukase H, Imazaki M, Shimizu K, Takeda S, et al. Concentration‐QTc analysis of soticlestat in healthy adults: An alternative to a thorough QT study. British Journal of Clinical Pharmacology. 2025. doi:10.1111/bcp.16255
BibTeX
@article{Yin2025,
author = {Yin, Wei and Dote, Nobuhito and Fukase, Hiroyuki and Imazaki, Manami and Shimizu, Kohei and Takeda, Shinichi and Darpo, Borje and Xue, Hongqi and Asgharnejad, Mahnaz},
title = {Concentration‐QTc analysis of soticlestat in healthy adults: An alternative to a thorough QT study},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1111/bcp.16255}
}
EUVIMED